These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22746187)

  • 41. Present-day treatment of tuberculosis and latent tuberculosis infection.
    Pérez-Camacho I; Rivero-Juárez A; Kindelán JM; Rivero A
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():41-6. PubMed ID: 21420566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
    Momin MAM; Tucker IG; Das SC
    Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis.
    Garg T; Rath G; Murthy RR; Gupta UD; Vatsala PG; Goyal AK
    Curr Pharm Des; 2015; 21(22):3076-89. PubMed ID: 26027577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.
    Johnson CM; Pandey R; Sharma S; Khuller GK; Basaraba RJ; Orme IM; Lenaerts AJ
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4335-8. PubMed ID: 16189115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
    Ahmad Z; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2005 Oct; 26(4):298-303. PubMed ID: 16154726
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis.
    Horváti K; Bacsa B; Kiss E; Gyulai G; Fodor K; Balka G; Rusvai M; Szabó E; Hudecz F; Bősze S
    Bioconjug Chem; 2014 Dec; 25(12):2260-8. PubMed ID: 25394206
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis.
    Ahmad Z; Sharma S; Khuller GK
    Nanomedicine; 2007 Sep; 3(3):239-43. PubMed ID: 17652032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities.
    Patil K; Bagade S; Bonde S; Sharma S; Saraogi G
    Biomed Pharmacother; 2018 Mar; 99():735-745. PubMed ID: 29710471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fighting tuberculosis: old drugs, new formulations.
    Blasi P; Schoubben A; Giovagnoli S; Rossi C; Ricci M
    Expert Opin Drug Deliv; 2009 Sep; 6(9):977-93. PubMed ID: 19678791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs.
    Pandey R; Sharma S; Khuller GK
    Indian J Exp Biol; 2004 Jun; 42(6):562-6. PubMed ID: 15260105
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quinoline: a promising antitubercular target.
    Keri RS; Patil SA
    Biomed Pharmacother; 2014 Oct; 68(8):1161-75. PubMed ID: 25458785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Niosomal encapsulation of the antitubercular drug, pyrazinamide.
    El-Ridy MS; Abdelbary A; Nasr EA; Khalil RM; Mostafa DM; El-Batal AI; Abd El-Alim SH
    Drug Dev Ind Pharm; 2011 Sep; 37(9):1110-8. PubMed ID: 21417612
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future.
    Mehta P; Bothiraja C; Kadam S; Pawar A
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S791-S806. PubMed ID: 30307321
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nanocarriers for respiratory diseases treatment: recent advances and current challenges.
    Trapani A; Gioia SD; Castellani S; Carbone A; Cavallaro G; Trapani G; Conese M
    Curr Top Med Chem; 2014; 14(9):1133-47. PubMed ID: 24678708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Macrophage Targeted Cellular Carriers for Effective Delivery of Anti-Tubercular Drugs.
    Agnihotri J; Singh S; Wais M; Pathak A
    Recent Pat Antiinfect Drug Discov; 2017; 12(2):162-183. PubMed ID: 29219058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Present status of nanoparticle research for treatment of tuberculosis.
    Shegokar R; Al Shaal L; Mitri K
    J Pharm Pharm Sci; 2011; 14(1):100-16. PubMed ID: 21501557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.
    Xu Y; Wu J; Liao S; Sun Z
    Ann Clin Microbiol Antimicrob; 2017 Oct; 16(1):67. PubMed ID: 28974222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy.
    Nemati E; Mokhtarzadeh A; Panahi-Azar V; Mohammadi A; Hamishehkar H; Mesgari-Abbasi M; Ezzati Nazhad Dolatabadi J; de la Guardia M
    AAPS PharmSciTech; 2019 Feb; 20(3):120. PubMed ID: 30796625
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery.
    Miranda MS; Rodrigues MT; Domingues RMA; Torrado E; Reis RL; Pedrosa J; Gomes ME
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():1090-1103. PubMed ID: 30274040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.